Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate.

Abstract

Weight gain has been cited by women as one of the main reasons for discontinuation of the contraceptive depot medroxyprogesterone acetate (DMPA). This study aimed to evaluate binge eating and the biochemical markers of appetite in new DMPA users. In this prospective non randomized study with adult healthy women, twenty-eight users of DMPA and twenty-five users of a copper intrauterine device (IUD) were paired for age (±1year) and body mass index (BMI) (±1kg/m2). We evaluated binge eating using the Binge Eating Scale (BES), the serum levels of neuropeptide Y, leptin and adiponectin, and the BMI at baseline and after 12months in both groups. For statistical analysis was used ANOVA for to compare the means of the repeated measurements. Mean age was 29.6 and 28.6years and BMI was 23.9 and 24.5kg/m2 for the DMPA and IUD groups, respectively. After 12months, the frequency of the scores of binge eating remained low in both groups. There were no significant differences between the groups at 12months with respect to BMI, levels of NPY, leptin, adiponectin, and BES scores. Healthy adult women did not present with central stimulation of appetite or binge eating disorder in their first year after starting use of DMPA. This study reinforces the use of the contraceptive DPMA and the need for guidance related to living a healthy lifestyle for women who attribute the increase of body weight to the use of the method.